StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics gains as Pfizer failure removes overhang
June 13, 2024 10:57 AM
Sarepta Therapeutics (NASDAQ: SRPT) stock rose over 3% Thursday after Pfizer (NYSE: PFE) announced disappointing results from its Phase 3 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Hot List
Next Articles
Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
June 13, 2024 7:59 AM
After-hours movers: Broadcom, Dave & Buster's, Oxford Industries, and more
June 12, 2024 4:45 PM
Sarepta Therapeutics (SRPT) Climbs After Pfizer (PFE) Study in DMD Fails
June 12, 2024 4:33 PM
Pfizer (PFE) Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys
June 12, 2024 4:30 PM
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
June 12, 2024 4:30 PM
Moderna (MRNA) price target raised at Oppenheimer after RSV vaccine approval
June 12, 2024 7:45 AM
